Mycophenolate mofetil does not modify the incidence of cytomegalovirus (CMV) disease after kidney transplantation but prevents CMV-induced chronic graft dysfunction

Journal of the American Society of Nephrology

Volumn 12, Issue 8, 2001, Pages 1758-1763

  Giral, M ^a   Nguyen, J M ^a   Daguin, P ^a   Hourmant, M ^a   Cantarovich, D ^a   Dantal, J ^a   Blancho, G ^a   Josien, R ^a   Ancelet, D ^a   Soulillou, J P ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE ACETATE;

ADULT; AGED; ARTICLE; CYTOMEGALIC INCLUSION BODY DISEASE; DISEASE SEVERITY; DRUG EFFECT; FEMALE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0034911679     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients
2. The role of PCR in the diagnosis and management of CMV in solid organ recipients
3. Impact of cytomegalovirus infection on organ transplant recipients
4. Effect of cytomegalovirus on a experimental model of chronic renal allograft rejection under triple-drug treatment in the rat
5. Association between cytomegalovirus and chronic rejection in kidney transplants recipients
6. Multicenter seroepidemiologic study of the impact of cytomegalovirus infection on renal transplantation
7. Cytomegalovirus infection: An etiological factor for rejection?
8. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients
9. Randomized trial efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-trans plant recipients
10. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation
11. Cytomegalovirus prophylaxis in solid organ transplant recipients
12. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo
13. Mycophenolate mofetil strongly potentiates the herpesvirus activity of acyclovir
14. Delayed graft function of more than 6 days strongly decreases long-term survival of transplanted kidneys
15. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: Randbmised comparison of two cyclosporin regimens
16. Randomized trial of an anti-interleukin 2 receptor monoclonal antibody (33B3.1) versus rabbit antithymocyte globulin (ATG) in prophylaxis of early rejection in human renal transplantation
17. A blind, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation
18. Mycophenolate mofetil in renal transplantation: 3-Year results from the placebo-controlled trial
19. Randomised comparison of triple therapy and antithymocyte globulin induction treatment after simultaneous pancreas-kidney transplantation
20. Consistent absorption of cyclosporine from a microemulsion formulation assessed in stable renal transplant recipients over a one year study period
21. Role of cytomegalovirus infection in allograft rejection: A review of possible mechanism
22. Rat cytomegalovirus infection and chronic kidney allograft rejection
23. Acute cytomegalovirus infection induces a subendothelial inflammation (endothelialitis) in the allograft vascular wall. A possible linkage with enhanced allograft arteriosclerosis
24. Cytomegalovirus antigen expression, endothelial cell proliferation, and intimal thickening in rat cardiac allografts after cytomegalovirus infection
25. Cytomegalovirus infection enhances the neo-intima formation in rat aortic allografts
26. Cytomegalovirus infection-enhanced cardiac allograft vasculopathy is abolished by DHPG prophylaxis in the rat
27. Prospective cohort of the conversion from mycophenolate mofetil (MMF) to azathioprine (AZA) after one year of transplantation
28. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection
29. Mycophenolate mofetil (MMF, RS-61443) inhibits inflammation and smooth muscle cell proliferation in rat aortic allografts
30. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors